Vapotherm to Host First Investor Day
Vapotherm, Inc. (NYSE: VAPO) announced its first investor day on June 23, 2021, starting at 10:00 AM ET. The event will take place at their Exeter, New Hampshire facilities, with a live webcast option available. Vapotherm specializes in high velocity therapy products that aid patients experiencing respiratory distress, having treated over 2.8 million patients. A replay of the webcast will be accessible for 90 days on their investor website. This initiative aims to enhance investor engagement, showcasing the company's innovative non-invasive respiratory technologies.
- None.
- None.
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be hosting their first investor day on Wednesday, June 23, 2021 beginning at 10:00AM ET.
The event will be held in person at the company’s facilities in Exeter, New Hampshire, and a portion of the day’s events will be accessible via a live webcast at https://event.on24.com/wcc/r/3199260/7822CB7A1D158353735CC9ACE696A86E.
A webcast replay will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.
About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
Website Information
Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005467/en/
FAQ
What is the date of Vapotherm's investor day?
Where will Vapotherm's investor day be held?
How can I access the webcast for Vapotherm's investor day?
Is there a replay available for Vapotherm's investor day?
What products does Vapotherm focus on?
How many patients have been treated using Vapotherm's products?
